Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tumor markers are ‘valuable’ for relapse detection in rare CNS tumors

Publish date:: June 26, 2020

Key clinical point: Tumor markers can be used to detect relapse in patients with CNS nongerminomatous germ cell tumors.

Major finding: Among evaluable patients, 92% of relapses were detectable by tumor markers.

Study details: A pooled analysis of clinical trial data from 483 patients.

Disclosures: Dr. Fonseca reported having no disclosures, and the researchers disclosed no funding for this study.

Citation:

Fonseca A et al. ASCO 2020, Abstract 2503.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CNS/Brain Cancer

Dexamethasone may ‘jeopardize’ benefit of immunotherapy in glioblastoma,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Immunotherapy could fill unmet need in leptomeningeal metastases,

Molecular features of medulloblastoma may help personalize radiotherapy,

‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients,